[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"influenza-like-illness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:influenza-like-illness":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,57,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100623422","effectiveness-and-implementation-of-a-national-guideline-for-acute-respiratory-tract-infections-to-reduce-antibiotic-prescribing-in-swiss-primary-care-100623422",false,"NCT07396428","Effectiveness and Implementation of a National Guideline for Acute Respiratory Tract Infections to Reduce Antibiotic Prescribing in Swiss Primary Care","Effectiveness and Implementation of a National Guideline for Acute Respiratory Tract Infections to Reduce Antibiotic Prescribing in Swiss Primary Care: the ImpProGUIDE Hybrid Type II Effectiveness-implementation Trial","ImpProGUIDE","Inclusion criteria for quality circles (QCs)\n\n* Willing to participate in a study mainly conducted in French\n* Agreeing to participate in evaluation surveys\n\nExclusion criteria for QCs\\*\n\n\\- Not having any physician included in the study\n\nInclusion criteria for walk-in clinics\n\n* The clinic offers general practice\u002Fprimary care medicine consultations, including emergencies\n* The clinic includes at least five physicians\n* The clinic has an \"Admission to practice charged to Swiss compulsory health insurance\"\n* The clinic plans to still be active in April 2026\n* Located in one of the following cantons: Vaud, Geneva, Valais, Fribourg, Jura, Neuchatel, Bern, Ticino.\n* Serving mainly adult patients\n* Willing to participate in the study\n\nPhysicians in QCs fulfilling all of the following inclusion criteria are eligible for the study:\n\n* Registered primary care physicians\n* Specialist title in general internal medicine or practicing physician.\n* Practicing in one of the following cantons: Vaud, Geneva, Valais, Fribourg, Jura, Neuchatel, Bern, Ticino.\n* Participating in a QC or working in an outpatient clinic participating in the study\\*.\n* Willing to participate in a study mainly conducted in French.\n* Agreeing to participate in evaluation surveys and agreeing to be invited to interviews\n\nEligibility criteria for physicians in clinics :\n\n\\- Having a clinical activity as primary care physician or supervising clinical activity of physicians in post-graduate training within a clinic included in the study\n\nThe only exclusion criterion for physicians is planning to retire before April 2026.\n\n\\*Note: not all physicians from a QC or a clinic are expected or required to participate individually in the study, but at least one should participate.","ALL",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","The ImpProGUIDE study aims to find out whether implementing new Swiss national guidelines for acute respiratory infections (ARI) can help to reduce antibiotic prescribing in primary care. In Switzerland, most antibiotics are prescribed in outpatient care, and many of these prescriptions may not be needed - especially when infections are caused by viruses, which antibiotics do not treat. Reducing overuse of antibiotics is important to slow the spread of antibiotic resistance.\n\nThe new guidelines were developed by the Swiss Society for Infectious Diseases (SSI) to support family doctors in managing ARIs, based on a syndromic approach. They recommend the targeted use of point-of-care C-reactive protein (CRP) testing when bacterial infection is suspected, as well as shared decision-making with patients.\n\nThis study will be carried out in quality circles (QCs) - small groups of family doctors who meet regularly to discuss and improve clinical practice - and in walk-in clinics in French- and Italian-speaking regions of Switzerland. Each will be randomly assigned to either an \"intervention\" group or a \"control\" group.\n\nIn the intervention group, QC moderators and medical center directors will receive implementation resources to lead a session and distribute materials to their group in autumn 2025 on the new guidelines. Doctors can then decide whether or not to use the recommendations in their consultations.\n\nIn the control group, QCs and centers will continue their regular activities. They will receive access to the same educational materials later, in summer 2026.\n\nThroughout the study, the researchers will collect de-identified data from health insurance billing records to track antibiotic prescribing and the use of diagnostic tests. Doctors and QC moderators will also be invited to complete short online surveys twice a year (10-15 minutes) and may be asked to join optional interviews or group discussions after the winter season.\n\nThe study will also explore the effectiveness of the implementation strategies on the adoption of the SSI guidelines, as well as the barriers and facilitators to adoption. This study type is known as a hybrid effectiveness implementation study, simultaneously evaluating an intervention's impact on antibiotic prescribing and the strategies used to implement the new national guidelines in a real-world setting.\n\nParticipation in the study is voluntary. Doctors can withdraw at any time. All data will be handled confidentially and in line with Swiss data protection laws.\n\nThe study is funded by the Swiss National Science Foundation. No support is received from pharmaceutical companies or manufacturers of diagnostic tests.",[26,27],"Acute Respiratory Infection","Influenza-like Illness",[29,30,31,32,33,34,35,36,37,38,39,40,41,42,43],"family medicine","primary care","implementation","hybrid design","effectiveness-implementation study","general medicine","outpatient","antibiotics","antibiotic prescribing","antimicrobial resistance","antimicrobial stewardship","guidelines","shared decision making","CRP","c-reactive protein","RECRUITING","2026-06-18",{"date":47,"type":48},"2026-06-24","ACTUAL",{"date":50,"type":48},"2025-05-19",{"date":52,"type":20},"2026-11",{"name":54,"class":55},"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland","OTHER",1,{"id":58,"slug":59,"hasResults":11,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":17,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":21,"phases":68,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":5},"100627844","clinical-assessment-of-respiratory-events-for-kids-integrating-diagnostics-and-stewardship-100627844","NCT07453914","Clinical Assessment of Respiratory Events for Kids: Integrating Diagnostics and Stewardship","CARE4KIDS","Inclusion Criteria:\n\n* Children from 60 days until less than 18 years old with signs and\u002For symptoms leading to suspicion of Respiratory Tract Infection (RTI) and\u002For Influenza-Like Illness (ILI), such as fever (Temperature greater than or equal to 37.8°C), rhinorrhea, nasal obstruction, sneezing, sore throat of pharyngeal pain, difficulties in breathing and\u002For cough, tachypnea, shortness of breath, apnea, croup.\n* Children and his\u002Fher legal representative who provide their informed consent.\n* Patients willing to provide a Nasopharyngeal Swab (NPS).\n\nExclusion Criteria:\n\n* Any condition that, in the opinion of the investigator\u002Fnurse results in significant immune dysfunction such as known primary immunodeficiency disorder, ongoing immunosuppressive therapy, known HIV infection, active or recent oncologic disease, transplant recipients and\u002For chronic use of immunomodulating agents,\n* Any condition that, in the opinion of the investigator\u002Fnurse, is related to severe patients requiring urgent referral who need to go on intensive care (such as patients who have a diagnosis of sepsis or septic shock,\n* Known pregnancy\n* Patients who refused to participate in the study and therefore declined Informed Consent Form.","60 Days","17 Years",{"count":67,"type":20},720,[23],"This study, called Care4Kids, aims to improve the management of respiratory infections in children visiting emergency departments. The research will evaluate the impact of using the BIOFIRE® SPOTFIRE® R\u002FST Panel, a rapid molecular point-of-care test, compared to standard care.\n\nChildren aged 2 months to 18 years with symptoms of respiratory tract infection or flu-like illness will be enrolled. After consent, participants will be randomly assigned to one of two groups:\n\n* Intervention group: The SPOTFIRE test will be performed immediately to guide treatment decisions.\n* Control group: Patients will receive standard care without the rapid test. The study will take place in three pediatric emergency departments in France, Greece, and Sweden. Up to 720 children will participate. A follow-up phone call will be made 14 days after the visit to check recovery and satisfaction.\n\nThe goal is to see whether rapid testing improves patient outcomes, reduces unnecessary treatments, and increases caregiver satisfaction.",[71,27,72],"Respiratory Tract Infections (RTI)","Children",[74,75,76,77,78,79,80,81,82,83,84],"Respiratory Tract Infection","Pediatric Respiratory Disease","Viral Respiratory Infection","Bacterial Respiratory Infection","children","Pediatrics","Stewardship","Diagnostic","Multicenter Study","Point Of Care Testing","multiplex Polymerase Chain Reaction.","NOT_YET_RECRUITING","2026-03-03",{"date":88,"type":48},"2026-03-06",{"date":90,"type":20},"2026-03",{"date":92,"type":20},"2026-09",{"name":94,"class":95},"BioMérieux","INDUSTRY",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":104,"maxAge":4,"enrollmentInfo":105,"targetDuration":107,"studyType":108,"phases":4,"briefSummary":109,"conditions":110,"keywords":115,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":56},"100614369","the-fever-clinic-acute-respiratory-cohort-100614369","NCT07278700","The Fever Clinic Acute Respiratory Cohort","The Fever Clinic Acute Respiratory Cohort (FACTS): A Prospective Real-World Cohort Study of Patients Presenting to Fever Clinics: Clinical Features, Laboratory and Radiographic Findings, and Long-Term Outcomes of Acute Respiratory Infections","FACTS","Inclusion Criteria:\n\n* Age ≥ 18 years (based on official identification document).\n* Presence of fever at the time of visit or within 24 hours prior to the visit, defined as a documented temperature of ≥37.3°C axillary\u002Ftympanic, ≥37.8°C orally, or ≥38.0°C rectally.\n* The primary cause of fever, as determined by the attending physician, is a respiratory tract infection.\n* Blood draw is required as part of standard clinical care.\n* Ability to comprehend the study's purpose, procedures, and potential risks, and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Inability to provide independent informed consent due to impaired consciousness or other reasons.\n* Inability to comply with the study procedures.\n* Medical contraindications to blood sampling, such as severe coagulopathy (e.g., INR \\> 3.0, platelet count \\\u003C 50 × 10⁹\u002FL).\n* Diagnosed with a terminal illness (e.g., advanced malignancy, severe multiple organ failure) and a life expectancy of less than 3 months.","18 Years",{"count":106,"type":20},1000,"30 Days","OBSERVATIONAL","This prospective cohort study aims to characterize the natural progression and outcomes of acute respiratory infections among patients presenting to fever clinics. At enrollment, patients' clinical symptoms, laboratory findings, and chest imaging data will be collected. Longitudinal follow-up will be conducted to evaluate disease progression, complications, and long-term outcomes.\n\nAs an observational study, no interventions are involved; all patients receive routine clinical management as directed by their attending physicians. This real-world study design enables the assessment of the natural course of acute respiratory infections and the identification of factors associated with clinical outcomes.",[111,112,113,114,27],"Acute Respiratory Infections","Febrile Illnesses","Community-acquired Pneumonia","Viral Respiratory Tract Infections",[116,117,118,119,120],"Respiratory Tract Infections","Fever","Community-Acquired Pneumonia","Anti-Bacterial Agents","Disease Progression","2025-12-11",{"date":123,"type":48},"2025-12-12",{"date":125,"type":48},"2025-10-10",{"date":127,"type":20},"2028-10",{"name":129,"class":55},"Fudan University"]